[HTML][HTML] Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis

L Chen, HX Yan, XW Liu, WX Chen - Medicine, 2020 - journals.lww.com
Background: To systematic review the efficacy and safety of 6-thioguanine (6-TG) in the
substitute of 6-mercaptopurine (6-MP) in the treatment for patients with childhood acute …

[HTML][HTML] LncRNA CRNDE promotes the progression of B-cell precursor acute lymphoblastic leukemia by targeting the miR-345-5p/CREB Axis

W Wang, F Wu, P Ma, S Gan, X Li, L Chen, L Sun… - Molecules and cells, 2020 - Elsevier
The imbalance between the proliferation and apoptosis of B-cell precursors is an important
contributor to the pathogenesis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) …

New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

C Simioni, F Bergamini, M Ferioli… - Hematological …, 2020 - Wiley Online Library
Acute lymphoblastic leukemia (ALL) represents a heterogeneous group of hematologic
malignancies, and it is normally characterized by an aberrant proliferation of immature …

Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes

Y Chen, Y Chen, Z Wu, J Li, Y Huang, X Peng… - Annals of …, 2024 - Springer
This study aimed to analyse the characteristics and treatment outcomes of adult patients with
acute lymphoblastic leukaemia (ALL) and construct nomogram predictive models for …

[HTML][HTML] Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that …

LM Sklarz, YS Gladbach, M Ernst, M Hamed… - Cancer cell …, 2020 - Springer
Background The introduction of combined conventional cytostatics and pathway-specific
inhibitors has opened new treatment options for several cancer types including hematologic …

[HTML][HTML] Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse

YS Gladbach, LM Sklarz, C Roolf, J Beck, E Schütz… - Genes, 2022 - mdpi.com
Little is known about optimally applying chemotherapeutic agents in a specific temporal
sequence to rapidly reduce the tumor load and to improve therapeutic efficacy. The clinical …

Upregulated miR-96-5p inhibits cell proliferation by targeting HBEGF in T-cell acute lymphoblastic leukemia cell line

K Xu, X Yan, G Ouyang, J Feng, L Ye… - Folia Histochemica et …, 2020 - journals.viamedica.pl
Introduction. microRNAs (miRNAs) are critical for tumorigenesis and progression of T-cell
acute lymphoblastic leukemia (T-ALL). MiR-96-5p has been shown to play important roles in …

[PDF][PDF] HEMOTERAPIA DO AMAZONAS PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIA

DASTCPO FREQUÊNCIA, COMLLEM AGUDA… - pos.uea.edu.br
As translocações cromossômicas são as principais alterações genéticas associadas com a
Leucemia Linfoide Aguda (LLA) e com a Leucemia Mieloide Aguda (LMA), sendo …

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia

RQ Lu, LX Wu, J Zhang, YZ Qin, YR Liu, YY Lai… - …, 2021 - Taylor & Francis
Objectives Ras-related dexamethasone-induced 1 (RASD1) is abnormally expressed in
many solid cancers. However, its potential role in adults with B-cell acute lymphoblastic …

[PDF][PDF] PRIMARY RESEARCH

LM Sklarz, YS Gladbach, M Ernst, M Hamed, C Roolf… - 2020 - cancerci.biomedcentral.com
Background: The introduction of combined conventional cytostatics and pathway‑specific
inhibitors has opened new treatment options for several cancer types including hematologic …